Leap Therapeutics : Net Proceeds, Along With Existing Cash, Cash Equivalents, & Marketable Securities Are Expected to Extend Cash Runway Into Q2 2026
Leap Therapeutics:淨收益以及現有現金、現金等價物和有價證券預計將把現金流延至2026年第二季度
Leap Therapeutics : Net Proceeds, Along With Existing Cash, Cash Equivalents, & Marketable Securities Are Expected to Extend Cash Runway Into Q2 2026
Leap Therapeutics:淨收益以及現有現金、現金等價物和有價證券預計將把現金流延至2026年第二季度
使用瀏覽器的分享功能,分享給你的好友吧